Carcinoma, Bronchogenic  >>  Zykadia (ceritinib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zykadia (ceritinib) / Novartis
NCT01685060 / 2012-003432-24: LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
2
140
Japan, US, Canada, Europe, RoW
LDK378, Ceritinib
Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
03/16
03/16
ASCEND-3, NCT01685138 / 2012-003474-36: LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Completed
2
124
Canada, Japan, US, Europe, RoW
LDK378, Ceritinib
Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
01/18
01/18
NCT02040870: LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Hourglass Apr 2017 - Jun 2017 : ASCEND-6 trial in ALK+ NSCLC
Completed
1/2
103
RoW
LDK378
Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
07/17
07/17

Download Options